Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
HALOthis companyHalozyme Therapeutics, Inc.	$102.17	25.49×	165.22×	5.77×	17.58×	-27.0%	83.6%	57.5%	22.7%	649.2%	23.2%	8.0%	43.89×	3.51×	44.28×	4.66×	0.0%	6	5.38	3	B
ALNYAlnylam Pharmaceuticals, Inc.	$156.13	166.38×	66.01×	14.03×	81.9×	-1017.9%	81.8%	13.5%	8.4%	39.8%	13.7%	0.9%	1.62×	-0.6×	1.99×	2.76×	0.0%	5	3.79	4	A-
LGNDLigand Pharmaceuticals Incorporated	$310.70	29.36×	3.59×	13.64×	20.41×	-87.1%	97.5%	17.6%	46.4%	12.2%	2.4%	1.3%	0.44×	1.43×	10.01×	22.23×	0.0%	5	3.83	2	C
Peer median	—	97.87×	34.8×	13.83×	51.15×	-552.5%	89.7%	15.6%	27.4%	26.0%	8.1%	1.1%	1.03×	0.42×	6×	12.49×	0.0%	5	3.81	3	—